L. Rodríguez-Díaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
L. Rodríguez-Díaz has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
J. Ribera-Perianes
Department of Nuclear Medicine, Hospital Clínic Barcelona, Barcelona, Spain
2 shared publicationsBelen Fernandez
Department of Nuclear Medicine. Central University Hospital of Asturias, Oviedo, Spain
1 shared publicationC. de Guirior
Gynaecology Department, Institute Clinic of Gynaecology, Obstetrics and Neonatology, Hospital Clinic, Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
1 shared publication- Carla Sitges
Department of Radiology, Hospital Clínic of Barcelona, 08036 Barcelona, Spain
1 shared publication - Carmen Vigil-Díaz
Department of Nuclear Medicine. Central University Hospital of Asturias, Oviedo, Spain
1 shared publication E. García
Department of Nuclear Medicine, Hospital Clínic Barcelona, Barcelona, Spain
1 shared publication
Latest Publications
- 24 September 2025
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 45 (2) , 500232
Selective sentinel lymph node biopsy in breast cancer local recurrence
- 24 September 2025
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 45 (2) , 500232
Selective sentinel lymph node biopsy in breast cancer local recurrence
- 30 September 2024
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 44 (2) , 500069
Radioactive seed localization technique with 125-I in inguinal endometriosis
- 30 September 2024
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 44 (2) , 500069
Radioactive seed localization technique with 125-I in inguinal endometriosis
- 19 September 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 45, 102043
Detection of small vegetations in native bi-valvular (aortic + mitral) infective endocarditis with 4D ECG-gated cardiac [18F]FDG PET/CT
- 19 September 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 45, 102043
Detection of small vegetations in native bi-valvular (aortic + mitral) infective endocarditis with 4D ECG-gated cardiac [18F]FDG PET/CT
- Open Access
- 29 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5142
Surgical Management and Its Impact on Adjuvant Treatment in Recurrent Ipsilateral Breast Cancer: A Retrospective Cohort Study
Background: Breast cancer (BC) recurrence, defined as the reappearance of cancer in the ipsilateral breast after primary treatment, poses significant challenges in clinical management. Despite advances in treatment, recurrence rates persist, ranging from 0.6 to 1.5% annually, reaching 10–15% at 20 years. This study aims to analyze the surgical and oncological characteristics of patients with BC recurrence. Methods: This retrospective study includes 56 patients diagnosed with recurrent BC between October 2018 and April 2022. Data were collected from a prospectively maintained surgical database. A descriptive analysis was performed on the initial BC, and the recurrence, including surgical complications, was classified using the Clavien–Dindo system. The success rates of selective sentinel lymph node (SLN) biopsies and aberrant drainages were assessed based on previous surgeries. Results: The cohort included 55 females and 1 male, with a median age of 65.3 years. The mean time to BC recurrence was 11.5 years. Among them, 26.8% underwent breast-conserving surgery, 41.1% had a mastectomy, 21.4% had a mastectomy with reconstruction, and 10.7% had an excision over a previous mastectomy. An SLN biopsy was performed in 78.6% of cases, with higher success rates in those without a previous axillary lymph node dissection (85.7% vs. 63.2%). Aberrant drainage was more frequent in patients with a previous ALND (44.4% vs. 20%). The median follow-up was 41.3 months, with 10.7% experiencing a second recurrence. Conclusions: Repeat breast-conserving surgery with re-irradiation for ipsilateral recurrence is feasible and does not significantly increase complications. SLN biopsy is valuable for restaging and tailoring adjuvant therapies, with ALND not being necessary if re-SLN biopsy shows no drainage. The management of aberrant drainage remains controversial.
- 29 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5142
Open AccessSurgical Management and Its Impact on Adjuvant Treatment in Recurrent Ipsilateral Breast Cancer: A Retrospective Cohort Study
Background: Breast cancer (BC) recurrence, defined as the reappearance of cancer in the ipsilateral breast after primary treatment, poses significant challenges in clinical management. Despite advances in treatment, recurrence rates persist, ranging from 0.6 to 1.5% annually, reaching 10–15% at 20 years. This study aims to analyze the surgical and oncological characteristics of patients with BC recurrence. Methods: This retrospective study includes 56 patients diagnosed with recurrent BC between October 2018 and April 2022. Data were collected from a prospectively maintained surgical database. A descriptive analysis was performed on the initial BC, and the recurrence, including surgical complications, was classified using the Clavien–Dindo system. The success rates of selective sentinel lymph node (SLN) biopsies and aberrant drainages were assessed based on previous surgeries. Results: The cohort included 55 females and 1 male, with a median age of 65.3 years. The mean time to BC recurrence was 11.5 years. Among them, 26.8% underwent breast-conserving surgery, 41.1% had a mastectomy, 21.4% had a mastectomy with reconstruction, and 10.7% had an excision over a previous mastectomy. An SLN biopsy was performed in 78.6% of cases, with higher success rates in those without a previous axillary lymph node dissection (85.7% vs. 63.2%). Aberrant drainage was more frequent in patients with a previous ALND (44.4% vs. 20%). The median follow-up was 41.3 months, with 10.7% experiencing a second recurrence. Conclusions: Repeat breast-conserving surgery with re-irradiation for ipsilateral recurrence is feasible and does not significantly increase complications. SLN biopsy is valuable for restaging and tailoring adjuvant therapies, with ALND not being necessary if re-SLN biopsy shows no drainage. The management of aberrant drainage remains controversial.